Ra‐224 labeling of calcium carbonate microparticles for internal α‐therapy: Preparation, stability, and biodistribution in mice
Open Access
- 12 March 2018
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 61 (6), 472-486
- https://doi.org/10.1002/jlcr.3610
Abstract
Internal therapy with α-emitters should be well suited for micrometastatic disease. Radium-224 emits multiple α-particles through its decay and has a convenient 3.6 days half-life. Despite its attractive properties, the use of 224Ra has been limited to bone-seeking applications because it cannot be stably bound to a targeting molecule. Alternative delivery systems for 224Ra are therefore of considerable interest. In this study, calcium carbonate (CaCO3) microparticles are proposed as carriers for 224Ra, designed for local therapy of disseminated cancers in cavitary regions, such as peritoneal carcinomatosis. CaCO3 microparticles were radiolabeled by precipitation of 224Ra on the particle surface, resulting in high labeling efficiencies for both 224Ra and daughter 212Pb and retention of more than 95 % of these nuclides for up to one week in vitro. The biodistribution after intraperitoneal administration of the 224Ra-labeled CaCO3 microparticles in immunodeficient mice revealed that the radioactivity mainly remained in the peritoneal cavity. In addition, the systemic distribution of 224Ra was found to be strongly dependent on the amount of administered microparticles, with a reduced skeletal uptake of 224Ra with increasing dose. The results altogether suggest that the 224Ra-labeled CaCO3 microparticles have promising properties for use as a localized internal α-therapy of cavitary cancers.Funding Information
- Norges Forskningsråd (235531, 237661)
This publication has 58 references indexed in Scilit:
- Preparation of hierarchical mesoporous CaCO3 by a facile binary solvent approach as anticancer drug carrier for etoposideNanoscale Research Letters, 2013
- The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective StudyPLOS ONE, 2010
- Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian CancerThe Journal of pharmacology and experimental therapeutics, 2008
- Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal PaclitaxelPharmaceutical Research, 2007
- Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and GrowthThe American Journal of Pathology, 2006
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclidesNuclear Medicine and Biology, 2004
- Distribution of intraperitoneally injected microspheres labeled with the α-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in miceGynecologic Oncology, 1992
- Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of Ovarian cancerCancer, 1992
- Radiocolloids in the Treatment of Ovarian CancerObstetrical & Gynecological Survey, 1979